202 related articles for article (PubMed ID: 2547748)
1. Synergy of clavulanic acid, sulbactam and tazobactam (YTR 830) with amoxycillin against fifty beta-lactamase-producing strains of Haemophilus influenzae.
Simonet M; Moittie D; Philippon A; Descamps P; Veron M
J Antimicrob Chemother; 1989 May; 23(5):798-800. PubMed ID: 2547748
[No Abstract] [Full Text] [Related]
2. [Comparison of the in vitro activity of amoxycillin + clavulanic acid and ampicillin + sulbactam combinations against 50 Haemophilus influenzae strains producing beta lactamase].
Moittie D; Simonet M; Veron M
Pathol Biol (Paris); 1989 May; 37(5):390-3. PubMed ID: 2789362
[TBL] [Abstract][Full Text] [Related]
3. In vitro activity of YTR 830.
Jacobs MR; Aronoff SC; Appelbaum PC; Yamabe S
J Chemother; 1989 Jun; 1(3):151-4. PubMed ID: 2552029
[TBL] [Abstract][Full Text] [Related]
4. Comparative activities of the beta-lactamase inhibitors YTR 830, sodium clavulanate, and sulbactam combined with amoxicillin or ampicillin.
Aronoff SC; Jacobs MR; Johenning S; Yamabe S
Antimicrob Agents Chemother; 1984 Oct; 26(4):580-2. PubMed ID: 6097169
[TBL] [Abstract][Full Text] [Related]
5. Beta-lactamase inhibitors and Acinetobacter spp.
Eng RH; Smith SM; Cherubin CE
J Antimicrob Chemother; 1990 Sep; 26(3):449-51. PubMed ID: 2172200
[No Abstract] [Full Text] [Related]
6. Antibacterial characteristics of YTR 830, a sulfone beta-lactamase inhibitor, compared with those of clavulanic acid and sulbactam.
Moosdeen F; Williams JD; Yamabe S
Antimicrob Agents Chemother; 1988 Jun; 32(6):925-7. PubMed ID: 2843088
[TBL] [Abstract][Full Text] [Related]
7. Comparative in vitro and in vivo activities of piperacillin combined with the beta-lactamase inhibitors tazobactam, clavulanic acid, and sulbactam.
Kuck NA; Jacobus NV; Petersen PJ; Weiss WJ; Testa RT
Antimicrob Agents Chemother; 1989 Nov; 33(11):1964-9. PubMed ID: 2558615
[TBL] [Abstract][Full Text] [Related]
8. Comparative activities of the beta-lactamase inhibitors YTR 830, clavulanate, and sulbactam combined with ampicillin and broad-spectrum penicillins against defined beta-lactamase-producing aerobic gram-negative bacilli.
Jacobs MR; Aronoff SC; Johenning S; Shlaes DM; Yamabe S
Antimicrob Agents Chemother; 1986 Jun; 29(6):980-5. PubMed ID: 3015017
[TBL] [Abstract][Full Text] [Related]
9. Comparative in vitro activities of amoxicillin-clavulanate, ampicillin-sulbactam and piperacillin-tazobactam against strains of Escherichia coli and proteus mirabilis harbouring known beta-lactamases.
Gatermann S; Marre R
Infection; 1991; 19(2):106-9. PubMed ID: 1646771
[TBL] [Abstract][Full Text] [Related]
10. Relative efficacy of tazobactam, sulbactam and clavulanic acid in enhancing the potency of ampicillin against clinical isolates of Enterobacteriaceae.
Pfaller M; Barry A; Fuchs P; Gerlach E; Hardy D; McLaughlin J
Eur J Clin Microbiol Infect Dis; 1993 Mar; 12(3):200-5. PubMed ID: 8389705
[TBL] [Abstract][Full Text] [Related]
11. Antibiotic interaction of amoxycillin and clavulanic acid against 132 beta-lactamase positive Haemophilus isolates: a comparison with some other oral agents.
Lapointe JR; Lavallée C
J Antimicrob Chemother; 1987 Jan; 19(1):49-58. PubMed ID: 3494009
[TBL] [Abstract][Full Text] [Related]
12. Comparative activity of beta-lactamase inhibitors YTR 830, clavulanate, and sulbactam combined with beta-lactams against beta-lactamase-producing anaerobes.
Appelbaum PC; Jacobs MR; Spangler SK; Yamabe S
Antimicrob Agents Chemother; 1986 Nov; 30(5):789-91. PubMed ID: 3026241
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of beta-lactamases by tazobactam and in-vitro antibacterial activity of tazobactam combined with piperacillin.
Higashitani F; Hyodo A; Ishida N; Inoue M; Mitsuhashi S
J Antimicrob Chemother; 1990 Apr; 25(4):567-74. PubMed ID: 2161820
[TBL] [Abstract][Full Text] [Related]
14. Selection of variants of the TEM-1 beta-lactamase, encoded by a plasmid of clinical origin, with increased resistance to beta-lactamase inhibitors.
Thomson CJ; Amyes SG
J Antimicrob Chemother; 1993 May; 31(5):655-64. PubMed ID: 8392995
[TBL] [Abstract][Full Text] [Related]
15. [The effectiveness of so-called potentiated penicillins (augmentin and tazobactam) in vitro].
Blahová J; Hupková M; Krcméry V
Cas Lek Cesk; 1995 Sep; 134(17):558-61. PubMed ID: 7553760
[TBL] [Abstract][Full Text] [Related]
16. Effect of low concentrations of clavulanic acid on the in-vitro activity of amoxycillin against beta-lactamase-producing Branhamella catarrhalis and Haemophilus influenzae.
Cooper CE; Slocombe B; White AR
J Antimicrob Chemother; 1990 Sep; 26(3):371-80. PubMed ID: 2121699
[TBL] [Abstract][Full Text] [Related]
17. Evolution of beta-lactamase inhibitors.
Rolinson GN
Rev Infect Dis; 1991; 13 Suppl 9():S727-32. PubMed ID: 1656513
[TBL] [Abstract][Full Text] [Related]
18. Variation in the potentiation of beta-lactam antibiotic activity by clavulanic acid and sulbactam against multiply antibiotic-resistant bacteria.
Aldridge KE; Sanders CV; Marier RL
J Antimicrob Chemother; 1986 Apr; 17(4):463-9. PubMed ID: 3011724
[TBL] [Abstract][Full Text] [Related]
19. Fixed or variable concentrations of beta-lactamase inhibitors in in-vitro tests?
Greenwood D
J Antimicrob Chemother; 1996 Jul; 38(1):17-20. PubMed ID: 8858452
[No Abstract] [Full Text] [Related]
20. Effect of beta-lactamase inhibitors on beta-lactamases from anaerobic bacteria.
Hedberg M; Lindqvist L; Tunér K; Nord CE
Eur J Clin Microbiol Infect Dis; 1992 Nov; 11(11):1100-4. PubMed ID: 1338315
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
